Tag : SYSTEMIC LUPUS ERYTHEMATOSUS

CONFERENCE UPDATE

Attaining LLDAS and reducing GC use with anifrolumab in SLE patients: The TULIP-LTE study
In patients with systemic lupus erythematosus (SLE), Lupus Low Disease Activity State (LLDAS) attainment is associated with reduced flares, oral glucocorticoid (GC) dosing, damage accrual, and mortality. The post-hoc analysis of the 52-week phase 3 TULIP-1/-2 trials showed that patients with SLE who received anifrolumab were more likely to achieve LLDAS over the placebo group.
CONFERENCE UPDATE

New insights on the impact of tapering GCs or immunosuppressive therapy on damage accrual after achieving LLDAS and complete remission SLE